#USA #LabConnect #Johnson City #Teddy Laboratory #Tigermed

Strategic Partnership Between Teddy Laboratory and LabConnect

In a significant move for the pharmaceutical and clinical research industries, Teddy Laboratory, a key subsidiary of Tigermed, has officially entered into a strategic cooperation agreement with LabConnect, LLC, a renowned global leader in central laboratory services. This partnership aims to create a comprehensive laboratory service ecosystem that spans both China and international markets, thereby facilitating innovation in drug development and commercialization.

The signing of this agreement marks a pivotal step for both companies. Under the terms of the agreement, Teddy Laboratory will serve as LabConnect's preferred laboratory partner within China. This collaboration will enable Teddy to furnish laboratory services adhering to international standards, which is particularly beneficial for multinational pharmaceutical companies conducting clinical trials within the Chinese market. On the flip side, LabConnect will assume the role of Teddy's preferred central lab partner for its international operations, leveraging its established presence in major markets like North America and Europe to assist Chinese pharmaceutical entities in their global expansion efforts.

During the signing ceremony, Ms. Xu Yi, Chairwoman of Teddy Laboratory and GuanHe Pharmaceuticals, emphasized the strategic alignment between the two companies. She acknowledged, “LabConnect’s distinctive business model perfectly complements Teddy’s localized strengths. Our previous collaborations, which began with our first Phase III clinical project in 2022, have been immensely successful.” This historical context sets a strong precedence for the future of their partnership, focusing on enhancing global clinical trial service standards.

Both organizations are committed to developing a long-term partnership model characterized by “China-based capabilities alongside a global service network.”

Jeff Mayhew, LabConnect's Chief Development Officer, stated, “By fully leveraging our respective resources and technological strengths, we aim to further enhance global clinical trial service standards.” This statement reinforces the intent behind their collaboration, aiming to redefine the laboratory services landscape.

The partnership is not merely about providing laboratory services; it symbolizes a broader strategy of integrating domestic and international central lab resources. Both companies have expressed a goal to continuously enhance their clinical trial capabilities, support innovative drug development, and ultimately deliver better treatment options to patients around the world.

About LabConnect

LabConnect stands out as a leading provider of Central Laboratory Services, offering comprehensive solutions that include FSP, scientific consulting, and data integration for complex clinical studies. Their expertise covers a variety of challenging fields, including immuno-oncology, gene and cell therapies, and the study of rare diseases. LabConnect combines cutting-edge technology with a straightforward approach to accessing both major and emerging markets, ensuring that drug developers can count on a unified service provider. More information can be found on their website LabConnect and on their LinkedIn profile.

About Teddy Laboratory/GuanHe Pharmaceuticals

Established in 2016, Shanghai GuanHe Pharmaceutical Technology Co., Ltd. is quickly evolving into a prominent force in the clinical research sector by offering innovative and integrated laboratory services. With branches located in several strategic cities, including Shanghai, Wuxi, Hangzhou, and Hong Kong, Teddy has positioned itself as a one-stop service provider for central laboratory and bioanalytical needs. Underwritten by Tigermed, Teddy supports clinical drug development through a comprehensive suite of services that span biomarker discovery, safety evaluation, and sample analysis among others. Notably, Teddy has assisted in the approval of 37 new drugs by China’s NMPA as of March 2025, further cementing its reputation in the market.

As Teddy Laboratory and LabConnect embark on this promising partnership, stakeholders within the pharmaceutical industry eagerly await the advancements that will follow in the realm of drug development and patient care.